Osteoporosis: Therapeutic guidelines. Guidelines for practice management of osteoporosis

Clinical Obstetrics and Gynecology

Volumn 56, Issue 4, 2013, Pages 694-702

  Khan, Sana N ^a   Craig, Latasha ^a   Wild, Robert ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Guidelines; Osteoporosis

Indexed keywords

ALCOHOL; ALENDRONIC ACID; BAZEDOXIFENE; CAFFEINE; CALCITONIN; CALCIUM; DENOSUMAB; ESTROGEN; GESTAGEN; IBANDRONIC ACID; LASOFOXIFENE; MAGNESIUM; PARATHYROID HORMONE[1-34]; RALOXIFENE; RETINOL; RISEDRONIC ACID; STRONTIUM RANELATE; TIBOLONE; TOBACCO SMOKE; VITAMIN D; ZOLEDRONIC ACID;

ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE MASS; BONE STRENGTH; BONE TURNOVER; BREAST CANCER; CALCIUM INTAKE; CANCER RISK; CARDIOVASCULAR RISK; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOMETRIUM CANCER; FALLING; FEMALE; FOLLOW UP; FRACTURE REDUCTION; FRAGILITY FRACTURE; HEART DISEASE; HIP FRACTURE; HORMONAL THERAPY; HUMAN; HYPERPARATHYROIDISM; KIDNEY FAILURE; MALABSORPTION; MUSCLE TRAINING; ORTHOPEDIC SURGERY; OSTEOLYSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; SMOKING CESSATION; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; WEIGHT BEARING; WOMEN'S HEALTH;

BONE DENSITY CONSERVATION AGENTS; COMBINED MODALITY THERAPY; DIETARY SUPPLEMENTS; HUMANS; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; UNITED STATES; VITAMIN D; VITAMINS;

EID: 84887796213     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/01.grf.0000437016.19989.61     Document Type: Article

References (6)

1. North American Menopause Society. Position statement: Management of osteoporosis in postmenopausal woman: 2010. Menopause. 2010;17: 25-54, quiz 55-6.
2. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Postmenopausal Osteoporosis. 2010. Available at: Https://www.aace. com/files/osteo-guidelines- 2010.pdf. Accessed February 4, 2013.
3. American College of Obstetricians and GynecologistsHauk L. Osteoporosis. Practice Bulletin. Number 129. 2012. Available at: Https://access. acog.org/eweb/dynamicpage.aspx?site=congress & webcode=LoginRequired & urlReq=http%3a%.%2fwww.acog.org%2fResources+And+Publi cations%2fPractice+Bulletins+List.aspx. Accessed January 16, 2013.
4. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: NOF; 2010. Available at: Http://nof.org/files/nof/public/content/file/344/ upload/159.pdf. Accessed February 5, 2013.
5. FDA Drug Safety Communication: Safety update for osteoporosis drugs, bisphosphonates, and atypical fractures 2010. Available at: Http://www.fda. gov/drugs/drugsafety/ucm229009.htm. Accessed March 2, 2013.
6. North American Menopause SocietyDiab DL, Watts NB. NAMS Practice Pearl: Use of drug holidays in women taking bisphosphonates. Menopause. 2013. Available at: Http://pdfs.journals.lww.com/meno pause journal/9000/00000/Use-of-drug- holidays-in-women-taking.98549.pdf. AccessedMarch 2, 2013.